Burkholderia pseudomallei Δ tonB Δ hcp1 Live Attenuated Vaccine Strain Elicits Full Protective Immunity against Aerosolized Melioidosis Infection
Abstract
In recent years, an increasing number of melioidosis cases have been reported in several regions where melioidosis is endemic and in areas where melioidosis had not commonly been diagnosed. Currently, the estimated burden of disease is around 165,000 new cases annually, including 89,000 cases that have fatal outcomes. This life-threatening infectious disease is caused by B. pseudomallei , which is classified as a Tier 1 select agent. Due to the high case fatality rate, intrinsic resistance to multiple antibiotic treatments, susceptibility to infection via the aerosol route, and potential use as a bioweapon, we have developed an effective live attenuated PBK001 vaccine capable of protecting against aerosolized melioidosis.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 27, 2019
- Source ID
- 10.1128/msphere.00570-18
Entities
People
- Alfredo G Torres
- Brittany N. Ross
- Daniel Tapia
- David H. Walker
- Janice J. Endsley
- Julia N. Myers
- Nittaya Khakhum
- Paul B. Kilgore
- Preeti Bharaj
Organizations
- Defense Threat Reduction Agency
- University of Texas Medical Branch